Purpose: This study aims to profile the expressions of 156 microRNAs (miRNA) in hepatocellular carcinoma (HCC) and to characterize the functions of miR-222, the most significantly upregulated candidate identified.
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related mortality. Over 560,000 new cases are diagnosed annually, and a roughly similar incidence of deaths has been reported yearly (1) . The overall poor survival of HCC patients is primarily attributed to the late disease presentation, which rules out curative surgery for the majority of patients (2) . The prognosis for the 10% to 20% of patients eligible for surgical resection remains dismal, as there is a high incidence of postoperative recurrences (3) . The generally poor clinical outcome of individuals diagnosed with HCC underscores the importance in obtaining a better understanding of the transcriptional activation of oncogenic signaling pathways, and the control of cancer-associated genes.
MicroRNAs (miRNA) belong to a class of endogenously expressed small noncoding RNAs (19-25 nucleotides in length) that regulate gene expression by either directing mRNA degradation or repressing posttranscriptional protein translation through binding to the 3′ untranslated region (UTR) of targeted gene transcript (4) . Increasing evidence suggests that miRNAs can mediate gene expression in a broad spectrum of regulatory pathways and are therefore believed to play essential roles in a range of biological processes. Although the precise function of many of the predicted ∼800 human miRNAs is still undefined, several cellular miRNAs have already been established as crucial regulators of cell growth, differentiation, and apoptosis by their control of critical tumor suppressors and oncogenes, for example the RAS by Let-7, BCL2 by miR-15a and miR-16-1, PTEN by miR-21, and E2F1 by miR-17∼miR-92 (5) (6) (7) (8) . Because a growing number of cancer-associated genes are now believed to be regulated by miRNAs, it is not surprising that miRNAs have also been implicated in the pathogenesis of cancer.
In this study, we profiled the HCC genome for deregulated miRNAs expression by quantitative PCR (qPCR) analysis. We identified the altered expressions of a distinct subset of miRNAs that underscored HCC development from the nonmalignant precursor of liver cirrhosis. The presence of cirrhosis was defined as the diffuse nodulation of liver composed of regenerating hepatocellular nodules surrounding the fibrous septa. Histologically, Ishak fibrosis score of 5 was used as a cutoff value for defining cirrhosis. Within the nontumorous liver parenchyma, an increase in fibrous tissue alone was not classified as cirrhosis but was considered as chronic hepatitis. Profound miR-222 overexpression was confirmed in a larger series of primary HCC tumors compared with nontumoral livers, and a strong relationship was established between the high expression of miR-222 with tumor progression and patient survival. In line with the associated clinicopathologic features, we determined a functional role for miR-222 in the cell migratory and the invasive advantages of HCC cells. Downstream investigation by gene expression profiling of miR-222 knockdown cells highlighted AKT signaling as the major pathway influenced by miR-222. Reduced AKT phosphorylation was verified by Western blot, which led us to further explore for protein phosphatases with complementary 3′UTR sequences to miR-222. By computational algorithm, the PPP2R2A gene, a component of the protein phosphatase 2A (PP2A), was predicted as a cellular target. We were able to corroborate the target association of miR-222 on the PP2A regulatory subunit B α isoform PPP2R2A by reporter assay and Western blot analysis. Our findings in this study highlight a new pathway for the regulation of AKT signaling in HCC.
Materials and Methods
Profiling of 156 human miRNAs (Applied Biosystems) was done on 20 HCC, 12 matching cirrhotic livers adjacent to the tumor (TN), and three cell lines (Hep3B, HKCI-4, and HKCI-9; ref. 9) by qPCR. Information on patient demographics is shown in Supplementary From the cohort of HCC patients studied, three patients received neoadjuvant therapy before curative surgery. One patient was given selective internal radiation therapy using 90 yttrium microspheres and two patients were treated with cisplatin/IFN α-2b/Adriamycin/fluorouracil combinatory chemotherapy. All samples were preserved by slow freezing in a block of Tissue-Tek O.C.T (Sakura Finetek) upon collection from the operation theatre. Three normal human liver controls acquired commercially were also included in our profiling study (Ambion, Clontech Laboratory, and Stratagene). Details of the methods used in the functional studies, immunoblottings, oligonucleotide expression array and pathway analysis, target prediction and luciferase reporter, and statistics are described in the supplementary document.
Results
Distinct miRNA pattern discriminates HCC from putative premalignant cirrhotic liver. Profiling of 156 miRNAs suggested the deregulation of 97 miRNAs in HCC tumors and cell lines compared with normal liver controls. Frequent incidences of upregulation of miRNAs, including miR-99a, miR-184, miR-224, and miR-222, were detected, whereas common downregulation was suggested for miR-325, miR-199a*, miR-199a, and miR-223 ( Supplementary  Fig. S1 ). To further define the miRNAs involved in HCC development, informatics analysis was deployed to determine and prioritize candidate miRNAs. Using a
Translational Relevance
Hepatocellular carcinoma (HCC) is a highly malignant tumor that leads rapidly to death. Recent advances in cancer biology have implicated changes in the endogenous expression of small microRNAs (miR-NA) as one of the most important controlling mechanisms in the expression of causative tumor-related genes in human cancers. Nevertheless, our knowledge of miRNA alterations in human HCC is limited. This study defined a distinct 40-miRNA signature in discriminating HCC tumors from adjacent nonmalignant cirrhotic liver tissue. The most significant event observed was the upregulation of miR-222. Increased miR-222 expression correlated with advanced stage HCC tumors and shorter disease-free survival of patients. The functional relevance of miR-222 was found in promoting HCC cell motility through enhancing AKT signaling, and target inhibition on protein phosphatase, PPP2R2A. The elucidation of deregulated miRNAs in HCC is expected to enhance the understanding on the tumor biology and serve as the basis for the further development of biomarkers in disease prognosis and therapies.
Wilcoxon test and limiting the false-positive discovery rate to 0% in significance analysis of microarrays (SAM) analysis, a distinct 40-miRNA expression pattern was defined in HCC tumors compared with nontumoral cirrhotic liver tissue (Fig. 1 ). Significant deregulation of 23 overexpressed and 17 repressed miRNAs was suggested (Table 1A and B). The 40-miRNA signature also ensured discriminatory clustering of HCC tumors from liver cirrhosis (Fig. 1) . Upregulated miR-222 was the most significant event observed among the 40 candidates concerned.
MiR-222 expression in HCC tumors. To further verify the importance of miR-222 in HCC, qPCR analysis was carried out to determine the miR-222 expressions in a cohort of 99 primary HCC tumors and 94 TN ( Table 2 ). Compared with normal livers, increased expressions of miR-222 were detected in as much as 98% of HCC (97 of 99 cases), in which a median 20.16-fold (quartiles, 6.93-125.00) was suggested. Elevated miR-222 expression was also observed in 86% of TN, with a median 4.98-fold (2.69-31.30). Raised expressions of miR-222 were similar in TN arising from a cirrhotic background and chronic hepatitis (P = 0.46). Overall, miR-222 seemed to be upregulated in 55% of HCC (52 of 94 pairs) with increased in expression ranging from 9.21-fold to >100-fold relative to adjacent TN (P < 0.0001; Fig. 2Ai) .
In correlative analyses with clinicopathologic features of tumors, we found a significant increase of miR-222 expressions in advanced stage HCC (P = 0.014; Fig. 2Aii ). In early T 1 tumors (n = 65), miR-222 expressions were Fig. 1 . Hierarchical clustering was done on 40 significant miRNAs derived from the SAM analysis. Two distinct dendrograms that coincided with HCC tumors (red bar) and the surrounding nontumorous liver tissue (green bar) were observed. Red, high expression levels; green, low expression levels. Some tumors were suggested at a closer distance to the cirrhotic liver tissue. These HCC-4, HCC-5, and HCC-7 cases were in fact early-stage T 1 tumors, which may explain in part their closer relation to their premalignant counterparts.
suggested at a median 16-fold (4.14-fold to 61.18-fold), whereas significantly higher miR-222 levels at a median of 35.52-fold (11.60-fold to 371.80-fold) were shown in advanced T 2 /T 3 tumors (n = 34). In the Kaplan-Meier analysis, high expressions of miR-222 correlated with poorer disease-free survival of patients (P = 0.011; hazard ratio, 2.214; 95% confidence interval, 1.188-3.829; Fig. 2Bi ) and shorter overall survival (P = 0.003; hazard ratio, 3.125; 95% confidence interval, 1.418-5.555; Fig. 2Bii ).
MiR-222 inhibition retarded HCC cell motility. Functional investigations of miR-222 by antisense experiments indicated negligible effects on cell viability in Hep3B and HKCI-9 cells (P ≥ 0.38; Fig. 3A) . However, significant inhibitions on cell migratory and invasive capacities were readily detected in anti-miR-222 transfectants. We found a considerable reduction in cell migration in Hep3B (64.5%, P = 0.008) and HKCI-9 (52.5%, ic>P = 0.048), and a similar decrease in cellular invasiveness in Hep3B (49.4%, P = 0.01) and HKCI-9 (45%, P = 0.015) between anti-miR-222 and mock experiments ( Fig. 3B and C) .
To further investigate the role of miR-222 in HCC cell motility, Phalloidin-stained actin filaments (filamentous actins) were examined in Hep3B cells following miR-222 inhibition. Confocal microscopy revealed a marked reduction of phorbol 12-myristate 13-acetate-induced spiky filopodia formation around the membrane peripherals of anti-miR-222-transfected cells (Fig. 3Dii) . The percentage of cells displaying reduced filopodia reached ∼40% at 24 hours and remained steady at 45% to 50% by 32 and 48 hours posttransfection (P = 0.027; Fig. 3Di ).
AKT signaling implicated as downstream modulated pathway of miR-222. To define the potential pathways modulated by miR-222 in the control of HCC cell motility, we performed microarray analysis on anti-miR-222-transfected Hep3B and HKCI-9 cells. Compared with mock transfection, specific deregulations of 691 and 1,350 known genes were identified in Hep3B and HKCI-9, respectively, in response to miR-222 suppression. A concordant upregulation of 44 and downregulation of 99 transcripts was suggested in both cell lines. Hierarchical clustering depicted discrete cluster dendrograms of antimiR-222 transfectants and mock controls (Fig. 4A) . Pathway analysis of common differentially expressed genes by ingenuity pathway analysis further highlighted functional networks, including cell-to-cell signaling, cellular movement, and cell development modulated by miR-222 (Table 3) . Cell-to-cell signaling was the most significant event observed in these biological networks, in which AKT signaling was the major pathway implicated (Table 3) . This finding prompted us to further investigate the effect of miR-222 inhibition on AKT expression. Although Western blot did not suggest an effect on the total AKT protein, miR-222 inhibition resulted in a consistent reduction of active phosphorylated AKT in Hep3B and HKCI-9 (Fig. 4C) .
PPP2R2A, a potential target of miR-222. Based on the effect shown on the level of active AKT, we reasoned that one of the downstream cellular targets of miR-222 was likely involved in the regulation of AKT phosphorylation. To this end, we used the TargetScan algorithm to highlight protein phosphatases with 3′UTR sequences complementary to miR-222. Predicted targets included five phosphatase genes, PPP2R2A, PPP3R1, PPP1R15B, PTPRZ1, and PPP6C. PPP2R2A was the only phosphatase among these potential candidates with a reported role in the control of AKT activity. A putative miR-222 binding site Fig. 2 . Ai, a significant upregulation of miR-222 was observed in HCC tumors compared with adjacent nonmalignant liver tissue (P < 0.0001). Aii, a significant association of high miR-222 expressions and advanced stage HCC was suggested (P = 0.014). Bi and Bii, Kaplan-Meier curves of the disease-free survival and overall survival for patients depending on miR-222 expressions. A high-level expression in the tumor was scored when a gain of 2-fold or more was achieved compared with adjacent nontumoral liver, whereas 2-fold loss or more was considered low expression. The overall survival rate in patients with high miR-222 expression (solid line) was significantly lower than in those with low miR-222 expression (dotted line; P ≤ 0.011). Fig. 3 . Ai and Aii, negligible effects on cell viability were suggested between anti-miR-222 and mock control experiments (P ≥ 0.38). Data from day 1 to day 7 posttransfection were shown. Bi, significant reductions in the chemotactic cell migration toward fetal bovine serum were observed in Hep3B and HKCI-9 cell lines transfected with anti-miR-222 compared with the mock control (P ≤ 0.048). Bii, a corresponding decrease in the invasive capacity was suggested in Hep3B and HKCI-9 cell lines following miR-222 suppression (P ≤ 0.015). Columns, mean of three individual experiments; bars, SEM. C, representative image of cells after migration through porous membrane of Transwell chamber is shown. Di, a significant reduction of filopodia was observed in anti-miR-222 transfectants compared with mock control following phorbol 12-myristate 13-acetate stimulation (2 μmol/L) at 24, 32, and 48 h posttransfection (P = 0.027). A profound decrease of filopodia was detected at 48 h posttransection. A total of 200 cells were scored for each condition. Columns, mean of three individual experiments; bars, SEM. Dii, representative images of Hep3B transfectants stained by TRITC-conjugated phalloidin to indicate actin filaments and counterstained by 4′,6-diamidino-2-phenylindole (DAPI) to indicate the nucleus is shown.
that comprised eight matched nucleotides was predicted at the 3′UTR of PPP2R2A (Fig. 4Bi) . Introduction of wildtype (WT) construct containing the WT PPP2R2A 3′UTR into Hep3B cells suggested a strong inhibition of luciferase activity compared with the mutant-deleted construct (P < 0.0001; Fig. 4Bii ). We further validated the specific interaction between miR-222 and the putative binding site of PPP2R2A transcript in the presence of miR-222 inhibition. Transfection of anti-miR-222 into Hep3B was able to restore the luciferase activity of WT construct by 30% (P = 0.0066; Fig. 4Biii ). By contrast, no effect on the luciferase signal was detected with the deleted construct. We were able to further substantiate the negative regulatory role of miR-222 on PPP2R2A by assessing the protein level of PPP2R2A in Hep3B and HKCI-9. Western blot analysis showed that the rescue of PPP2R2A protein expression could be consistently detected in both cell lines in response to anti-miR-222 transfection compared with the mock control (Fig. 4C) .
Discussion
This study reports on a qPCR-based miRNA profiling in HCC. Using informatic analysis, we were able to identify a 40-miRNA signature that underlined the hepatic transformation from liver cirrhosis. Several studies have recently reported on the miRNA profiling of liver cancer Fig. 4 . A, two distinct dendrograms that represent Hep3B and HKCI-9 transfected with anti-miR-222 and mock control are shown. Red, high expression levels; green, low expression levels. Bi, base pairing complement suggested the putative miR-222 binding position at 452 to 457 of the PPP2R2A 3′UTR. The firefly luciferase activity was standardized to Renilla control. Bii, a strong inhibition of luciferase activity was observed in Hep3B cells transfected with WT construct (P < 0.0001) compared with the DEL construct; MUT, mutant. Biii, a significant increase in luciferase activity was detected in Hep3B cells transfected with anti-miR-222 compared with mock control RNA (P = 0.0066). Columns, mean of three individual experiments; bars, SEM. C, Western blot analysis suggested the consistent reductions of phosphorylated AKT in anti-miR-222-transfected Hep3B and HKCI-9 cells compared with mock controls, whereas total protein levels remained unchanged. An increased PPP2R2A protein level was detected in Hep3B and HKCI-9 cell lines after miR-222 inhibition. Table 3 . Pathways implicated in the miR-222 inhibition by ingenuity pathway analysis (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , and several deregulated miRNAs identified in this study was common to those previously published. Examples include the upregulation of miR-301, miR-224, miR-21, miR-221, and miR-222, and the downregulation of miR-199a*, miR-199a, miR-195, miR-214, and miR-223. Ura and coworkers (22) reported on a unique 23-miRNA cluster, which could differentiate HCC tumors from noncancerous chronic hepatitis liver tissue, irrespective of HBV or HCV infection. Many of these 23 miRNAs were also found to be deregulated in the 40-miRNA pattern determined in this study, e.g., miR-222, miR-183, miR-199a*, and miR-125b. Identification of the same miRNA deregulations in different studies may further imply their importance in liver tumorigenesis.
The upregulation of miR-222 was the most significant event observed in our study. Using Northern blot analysis, previous studies both by our group and others have shown that expressions of miR-222 were often higher in HCC tumors than in the adjacent nontumoral liver tissue. The prognostic value and functional implications of miR-222 in HCC, however, remain largely undefined. Here, based on qPCR analysis on a large cohort of primary HCC tumors, we were able to establish a significant link between the level of miR-222 expression, and tumor progression and disease-free survival of patients. Consistent with our findings, miR-222 has earlier been implicated in HCC progression from an inverse correlation shown with tumor differentiation (20) . Upregulations of miR-222 have been described in prostate cancer, primary glioblastoma, papillary thyroid carcinoma, and breast cancer, and a possible functional role for miR-222 in cell growth and proliferation has been proposed, through its influence on the expression of cell cycle regulatory proteins such as the cyclin-dependent kinase inhibitor p27Kip1 (24) (25) (26) . In this study, inhibition of miR-222 activity did not seem to exert an effect on cell viability in Hep3B and HKCI-9. However, a substantial reduction in the invasive phenotype and chemotactic migrations was readily observed in both cell lines. Our functional investigations hence suggest an oncogenic role for miR-222 in promoting cellular invasiveness and motility in HCC cells. Phalloidin staining of filamentous actins showed a marked decrease in filopodia formation in anti-miR-222-transfected cells. This finding further affirmed an effect of miR-222 on the motile phenotype of HCC through the structural organization of filopodia at the leading edge of migrating cells.Consistent with this finding, a recent study by Felicetti et al. (27) reported that ectopic expression of miR-222 could elevate the migratory and invasive behaviors of melanoma cells.
Expression profiling of anti-miR-222-transfected Hep3B and HKCI-9 highlighted AKT signaling as a major pathway under the influence of miR-222. In HCC, phosphoinositide 3-kinase/AKT signaling is one of the more important oncogenic pathways and is frequently activated during the liver tumorigenesis (28, 29) . Immunohistochemical studies have shown that the common phosphorylation status of AKT correlated with vascular invasion and intrahepatic metastasis in HCC (28, 29) . It has also been suggested that AKT phosphorylation is a risk factor for early disease recurrences and poor prognosis of HCC patients (30) . In vitro functional studies have further shown that the AKT pathway is a critical mediator in the control of HCC cell invasion and motility (31, 32) . In this study, we showed that miR-222 inhibition could induce a profound reduction in AKT phosphorylation, which in turn would support the potential role of miR-222 in AKT activation. Because the evident reduction of active AKT was not accompanied by a decrease in total AKT, we reasoned that miR-222 regulated AKT activity in the process of dephosphorylation. We therefore examined several protein phosphatases for the presence of complementary 3′UTR sequences to miR-222, which led us to identify PPP2R2A as a potential downstream target.
PPP2R2A is a regulatory subunit of PP2A (33) . PP2A is a well-conserved essential protein serine/threonine phosphatase in eukaryotes and is a well-recognized regulator in the control of AKT activity. Kuo et al. (14) have confirmed a direct interaction between PPP2R2A and AKT by in vitro pull-down assay, and have further shown that PPP2R2A is required for targeting PP2A to AKT in prolymphoid FL5.12 cells. More importantly, the ectopic expression of PPP2R2A has been shown to impair phosphorylation at the Ser-473 and Thr-308 residues of AKT (14) . In a functional context, PP2A has been implicated in modulating cell motility in lung cancer cells and fibroblasts (34, 35) . Here, using reporter assay and Western blot, we showed that miR-222 could target and suppress PPP2R2A protein translation. Given the reported role of PPP2R2A in AKT dephosphorylation, we propose that PPP2R2A is a likely intermediate that interplays between miR-222 and the AKT signaling path.
In conclusion, this study has highlighted a potential prognostic value of miR-222. Although increased levels of miR-222 were more profound in tumors, they could also be detected in the premalignant lesions of adjacent TN. The stepwise elevation of miR-222 expressions from TN to early HCC and late-stage tumors would imply miR-222 activation in the early transcriptional dysregulations of liver carcinogenesis and its contribution to both the developmental and malignant progressions of HCC.
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